Citi Research forecasts Square can grow its sales by 29 percent annually through 2019. » Read More
By: Dan Mangan
UnitedHealth denies allegations it gamed the nation's Medicare system for hundreds of millions of dollars. » Read More
By: John Melloy
Fundstrat says the Facebook, Amazon, Netflix and Google-parent Alphabet stocks basket now has a value of $1.3 trillion. » Read More
By: Evelyn Cheng
Kraft Heinz's proposed Unilever merger marks another consolidation effort in the food industry by 3G Capital and Warren Buffett's Berkshire Hathaway. » Read More
Jim Cramer has noticed a secret pattern behind the price of oil, and goes step by step to reveal how it works.
Jim Cramer highlights one of the best oil moves he has ever seen.
Jim Cramer found the one stock that is not connected to the Federal Reserve that could go on a run regardless of what happens Wednesday.
The "Fast Money" traders debated how investors should position their portfolios ahead of two major central bank meetings.
Stocks of companies in the same industry groups are starting to move in lockstep — a sign to some strategists that stocks will go higher.
Deutsche Bank told clients which stocks to buy if Trump or Clinton gets elected.
Apple's shares are slipping on Monday, but trader Todd Gordon sees a big opportunity to make money on the tech giant's next move.
Wynn Resorts fell as much as 4 percent Monday after researcher Nomura cited mass-market softness at the company's recently opened Macau property.
Jim Lebenthal, who's up 31 percent this year in his CNBC PRO model portfolio, sells Apple.
Stocks have a lot of runway to put up gains as investors chase high-performing equities and seasonal strength kicks in, Tom Lee said.
Wells Fargo's $185 million settlement, and Mylan's EpiPen mess were about corporate greed, the Aspen Institute CEO says.
Baird raises its rating for Wells Fargo to outperform from neutral.
Jim Cramer fired back on critics who claimed that Apple's iPhone 7 sales wouldn't be as good, if Samsung didn't have its Galaxy Note 7 recall.
The bank’s scandal won’t have meaningful effect on its balance sheet, Baird analysts say.
Shares of Sarepta Therapeutics briefly surge after the FDA approved its muscular dystrophy drug eteplirsen.
Morgan Stanley upgrades shares of General Motors to overweight, predicting a 19 percent rally in the next 12 months.
JPMorgan reiterates its overweight rating on Apple but is cautious on near term iPhone sales.
History suggests the rally will continue, according to perennial bull Tom Lee. That means the S&P's recent dip "needs to be bought aggressively."
Some of the names on the move ahead of the open.
CNBC senior markets commentator Mike Santoli describes the investment case for Apple.
Get the best of CNBC in your inbox